Concepedia

Author

Patrick R. Verhoest

Pfizer (United States)

Also Known As

P Verhoest, P. R. VERHOEST, P. Verhoest, P.R. Verhoest, Patrick R Verhoest, Patrick R. Verhoest, Patrick Verhoest, Verhoest, Patrick R., Verhoest, Patrick Robert

108

Publications

7.2K

Citations

32

H-Index

98

Concepts

All Affiliations

Pfizer (United States)Monell Chemical Senses CenterUniversity of PennsylvaniaUtah State UniversityCentre Hospitalier Universitaire Amiens-Picardie
PR

About

Patrick R. Verhoest is an author at Pfizer (United States) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

23

28

5.1K

2

Natural Sciences

19

19

1.4K

3

Engineering

4

4

1.2K

4

Health Sciences

1

1

18

5

Public Health

1

1

83

Patrick R. Verhoest

×

54

Publications

7K

Citations

32

H-Index

YearCitations

An oral SARS-CoV-2 M <sup>pro</sup> inhibitor clinical candidate for the treatment of COVID-19

Dafydd R. Owen, Charlotte Allerton, Annaliesa S. Anderson,

Science

2021

1.8K

Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties

Travis T. Wager, Xinjun Hou, Patrick R. Verhoest,

ACS Chemical Neuroscience

2010

1K

Central Nervous System Multiparameter Optimization Desirability: Application in Drug Discovery

Travis T. Wager, Xinjun Hou, Patrick R. Verhoest,

ACS Chemical Neuroscience

2016

564

Defining Desirable Central Nervous System Drug Space through the Alignment of Molecular Properties, in Vitro ADME, and Safety Attributes

Travis T. Wager, Ramalakshmi Y. Chandrasekaran, Xinjun Hou,

ACS Chemical Neuroscience

2010

476

Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia

C J Schmidt, Douglas S. Chapin, J. Cianfrogna,

Journal of Pharmacology and Experimental Therapeutics

2008

284

Total Synthesis of (+)-Phorboxazole A Exploiting the Petasis−Ferrier Rearrangement

Amos B. Smith, Kevin P. C. Minbiole, Patrick R. Verhoest,

Journal of the American Chemical Society

2001

219

Discovery of a Novel Class of Phosphodiesterase 10A Inhibitors and Identification of Clinical Candidate 2-[4-(1-Methyl-4-pyridin-4-yl-1 <i>H</i> -pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the Treatment of Schizophrenia†Coordinates of the PDE10A crystal structures have been deposited in the Protein Data Bank for compound 1 (3HQW), 2 (3HQY), 3 (3HQW) and 9 (3HR1).

Patrick R. Verhoest, Douglas S. Chapin, Michael L. Corman,

Journal of Medicinal Chemistry

2009

201

Design and Selection Parameters to Accelerate the Discovery of Novel Central Nervous System Positron Emission Tomography (PET) Ligands and Their Application in the Development of a Novel Phosphodiesterase 2A PET Ligand

Lei Zhang, Anabella Villalobos, Elizabeth M. Beck,

Journal of Medicinal Chemistry

2013

199

Discovery and Preclinical Profiling of 3-[4-(Morpholin-4-yl)-7 <i>H</i> -pyrrolo[2,3- <i>d</i> ]pyrimidin-5-yl]benzonitrile (PF-06447475), a Highly Potent, Selective, Brain Penetrant, and in Vivo Active LRRK2 Kinase Inhibitor

Jaclyn L. Henderson, Bethany L. Kormos, Matthew M. Hayward,

Journal of Medicinal Chemistry

2014

178

(−)-Spiro[1-azabicyclo[2.2.2]octane-3,5‘-oxazolidin-2‘-one], a Conformationally Restricted Analogue of Acetylcholine, Is a Highly Selective Full Agonist at the α7 Nicotinic Acetylcholine Receptor

G. B. MULLEN, James Napier, Michael Balestra,

Journal of Medicinal Chemistry

2000

132

Page 1